Aprogen Biologics Inc

Aprogen Biologics Inc has a debt-to-equity ratio of 0.8, indicating a relatively balanced capital structure. However, the company's operating cash flow is negative at -38,232,646,550 KRW, and capital expenditures are also negative at -9,779,603,410 KRW, suggesting ongoing cash outflows. The company's cash and equivalents amount to 24,392,535,690 KRW, which is insufficient to cover its long-term debt of 228,343,747,040 KRW, resulting in a net cash deficit. In terms of profitability, Aprogen Biologics Inc's revenue for the latest period is 73,226,140,160 KRW. The company's profitability metrics, such as return on invested capital (ROIC) and operating margins, are not provided, but the negative operating cash flow indicates potential challenges in generating consistent cash from operations. The company's revenue is derived from two segments: the Medicine Business and the Gaming Business. The Medicine Business segment includes pharmaceuticals and cosmetics, while the Gaming Business segment focuses on role-playing games. However, the input data does not provide specific revenue concentrations for each segment or geographic regions, making it difficult to assess the extent of revenue diversification. The company's growth trajectory is not clearly defined in the input data. The financial snapshot does not include historical revenue data or future outlooks, which are necessary to determine the company's growth potential. The absence of detailed growth metrics limits the ability to assess the company's future performance. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which could pose liquidity challenges. The low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near term. Recent events, such as filings and transcripts, are not provided in the input data, which limits the ability to assess the company's recent performance and strategic direction. The absence of recent events makes it difficult to evaluate the company's response to market conditions and regulatory changes.